An antiviral peptide targets a coiled-coil domain of the human T-cell leukemia virus envelope glycoprotein.
about
Charge-Surrounded Pockets and Electrostatic Interactions with Small Ions Modulate the Activity of Retroviral Fusion ProteinsHeptad repeat 2-based peptides inhibit avian sarcoma and leukosis virus subgroup a infection and identify a fusion intermediateCandidate polyanionic microbicides inhibit human T-cell lymphotropic virus type 1 receptor interactions, cell-free infection, and cell-cell spread.A study of low pH-induced refolding of Env of avian sarcoma and leukosis virus into a six-helix bundle.Conformation-specific antibodies targeting the trimer-of-hairpins motif of the human T-cell leukemia virus type 1 transmembrane glycoprotein recognize the viral envelope but fail to neutralize viral entryCellular Factors Involved in HTLV-1 Entry and PathogenicitLong Terminal Repeat Circular DNA as Markers of Active Viral Replication of Human T Lymphotropic Virus-1 in Vivo.Intersubunit disulfide isomerization controls membrane fusion of human T-cell leukemia virus EnvDiscovery and significance of new human T-lymphotropic viruses: HTLV-3 and HTLV-4.Interaction between the HTLV-1 envelope and cellular proteins: impact on virus infection and restriction.Receptor-triggered but alkylation-arrested env of murine leukemia virus reveals the transmembrane subunit in a prehairpin conformation.Residues within the C-terminal arm of the herpes simplex virus 1 glycoprotein B ectodomain contribute to its refolding during the fusion step of virus entry.Nonhelical leash and alpha-helical structures determine the potency of a peptide antagonist of human T-cell leukemia virus entry.Expanded tropism and altered activation of a retroviral glycoprotein resistant to an entry inhibitor peptide.AVP-IC50 Pred: Multiple machine learning techniques-based prediction of peptide antiviral activity in terms of half maximal inhibitory concentration (IC50).The SCHOOL of nature: IV. Learning from viruses.Highly specific inhibition of leukaemia virus membrane fusion by interaction of peptide antagonists with a conserved region of the coiled coil of envelope.Oligomerization of hantavirus nucleocapsid protein: analysis of the N-terminal coiled-coil domain.Basic residues are critical to the activity of peptide inhibitors of human T cell leukemia virus type 1 entry.Structural characterization of the SARS-coronavirus spike S fusion protein core.Resistance to neutralization by antibodies targeting the coiled coil of fusion-active envelope is a common feature of retroviruses.
P2860
Q27666913-B29CE29D-168F-4CC0-BABA-86D2265CB253Q30448708-4D4751F5-4F8A-40CE-B789-9CE66949EFD8Q33388659-FCE4FCE4-25AF-4163-BCF9-E686CE77D292Q34187711-8345D8A6-3380-48D9-9139-E38FA27678CBQ35857748-27CE0499-FBA9-495A-A86B-CBA4EF0B2054Q36049779-0816E6CA-B42E-42C8-9DA5-5E020619F761Q36735681-74A3EA75-0FE3-4345-8BB4-22AE0FE20B82Q36747774-85B01915-6613-46AE-9AC7-C7410D57BC84Q37646720-73D7AA6F-8B2F-4EA0-9C61-B6C2665525FCQ37856298-30ACAF4A-E6DC-4E04-8862-BA8BA0C9AE2EQ38761263-A95CFB69-128C-41CF-BCFB-5F5536210D10Q39366614-B49140A4-F1D7-4E26-83CA-FAE0855096AFQ40008331-2890C068-0C26-4479-BE5E-163936CE768BQ40340446-9C7B17C5-491C-4E97-B496-A2EED04ABEE8Q40693694-E35CEA3A-1EEA-4A8A-B7B1-98624C71E7BAQ41776844-CF8B0960-AC25-495C-82A1-3BBA94317901Q41834173-3C9D4A91-7A92-4F98-BA50-C86B2FBDA12CQ43158249-84B1364D-6E30-492B-A77E-B8CF4D4BF155Q44344274-41C1338D-4040-44F9-9505-2BC82AC98D17Q48009341-A701C91E-E6B9-4D47-8744-533631109E44Q52582819-A3AFDC6D-1A6C-4C8C-BCBB-8979D78FFE4E
P2860
An antiviral peptide targets a coiled-coil domain of the human T-cell leukemia virus envelope glycoprotein.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
An antiviral peptide targets a ...... a virus envelope glycoprotein.
@ast
An antiviral peptide targets a ...... a virus envelope glycoprotein.
@en
An antiviral peptide targets a ...... a virus envelope glycoprotein.
@nl
type
label
An antiviral peptide targets a ...... a virus envelope glycoprotein.
@ast
An antiviral peptide targets a ...... a virus envelope glycoprotein.
@en
An antiviral peptide targets a ...... a virus envelope glycoprotein.
@nl
prefLabel
An antiviral peptide targets a ...... a virus envelope glycoprotein.
@ast
An antiviral peptide targets a ...... a virus envelope glycoprotein.
@en
An antiviral peptide targets a ...... a virus envelope glycoprotein.
@nl
P2093
P2860
P1433
P1476
An antiviral peptide targets a ...... a virus envelope glycoprotein.
@en
P2093
David W Brighty
Jack U Flanagan
Josefina D Piñón
Nicholas C Price
P2860
P304
P356
10.1128/JVI.77.5.3281-3290.2003
P407
P577
2003-03-01T00:00:00Z